No article text was recorded for this version.
anti-VEGF resistance
Version 2 of 219 papers23 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration – 6 month results after completion of the loading phase
- Blog: Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes
- Blog: Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept
- Blog: Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review
- Blog: Automatic quantification of retinal photoreceptor integrity to predict persistent disease activity in neovascular age-related macular degeneration using deep learning
- Blog: Predictive value of hyperreflective foci for anti-VEGF therapeutic outcomes in different subtypes of diabetic macular edema: a retrospective analysis
- Blog: Small RNA Sequencing Reveals Transfer RNA-derived Small RNA Expression Profiles in Retinal Neovascularization
- Blog: Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial
- Blog: Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema
- Blog: Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results
- Blog: Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab
- Blog: Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration
- Blog: Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
- Blog: DeepPDT-Net: predicting the outcome of photodynamic therapy for chronic central serous chorioretinopathy using two-stage multimodal transfer learning
- Blog: Renal dysfunction associated with clinical response to intravitreal conbercept therapy for diabetic macular edema
- Blog: A machine learning model for predicting anatomical response to Anti-VEGF therapy in diabetic macular edema
- Blog: Endothelial cells-targeted soluble human Delta-like 4 suppresses both physiological and pathological ocular angiogenesis
- Blog: Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration
- Blog: Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_anti_vegf_resistance_c6bc3384,
title = {anti-VEGF resistance},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/anti-vegf-resistance/rdr_c6bc3384da84462ab68e1e0c25f1e92a},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}This exact version (version 2, frozen text):
@misc{lacuna_anti_vegf_resistance_c6bc3384_v2,
title = {anti-VEGF resistance},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/anti-vegf-resistance/rdr_c6bc3384da84462ab68e1e0c25f1e92a/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-22},
}